6533b832fe1ef96bd129ad6d

RESEARCH PRODUCT

Autoimmune polyglandular diseases.

George J. KahalyLara Frommer

subject

0301 basic medicinePediatricsmedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismFamilial clusteringClinical manifestationEndocrine System DiseasesAutoimmune Diseases03 medical and health sciences0302 clinical medicineEndocrinologyQuality of lifeMedicineHumansIn patientStage (cooking)Polyendocrinopathies AutoimmuneSubclinical infectionPatient Care Teambusiness.industrymusculoskeletal neural and ocular physiologyIncidence030104 developmental biologycardiovascular systemQuality of LifeInterdisciplinary CommunicationHigh incidenceMorbiditybusinessPsychosocialcirculatory and respiratory physiology

description

Autoimmune polyglandular diseases (APD) are defined as the presence of two autoimmune -induced endocrine failures. With respect to the significant morbidity and potential mortality of APD, the diagnostic objective is to detect APD at an early stage, with the advantage of less frequent complications, effective therapy and better prognosis. This requires that patients at risk be regularly screened for subclinical endocrinopathies prior to clinical manifestation. Regarding the time interval between manifestation of first and further endocrinopathies, regular and long-term follow-up is warranted. Quality of life and psychosocial status are poor in APD patients and involved relatives. Familial clustering is high in patients with APD. Considering the high incidence of one or more endocrinopathies in first-degree relatives of patients with APD, family members should be regularly screened since they may also develop autoimmune endocrinopathies. Multidisciplinary management of these multiplex families in specialized centers is warranted.

10.1016/j.beem.2019.101344https://pubmed.ncbi.nlm.nih.gov/31606344